Singapore’s national precision-medicine agency (PRECISE) and Temasek-backed technology firm Temus will jointly build the data and computing systems for the next phase of the country’s effort to sequence hundreds of thousands of residents’ genomes.

In a statement on Friday, PRECISE said the two have signed a memorandum of understanding to establish a five-year PRECISE-Temus Joint Innovation Centre supporting Phase III of Singapore’s National Precision Medicine program. The signing, at a precision-health event, was witnessed by Health Minister Ong Ye Kung.

Phase III, launched in November 2025 and running to 2031, aims to sequence the whole genomes of about 450,000 residents, or a tenth of Singapore’s resident. It can build on 100,000 sequenced in the previous phase and test the use of genomic data in clinical care at scale.

The center will develop shared platforms to process and analyze whole-genome data and build safeguards for handling it securely, the partners said. It builds on work the two have done since 2024 on a genomics data system that handles about 13.6 PB of data. It is upgrading past 60 PB, cutting processing times from weeks to days.

The center also aims to train specialists in fields such as computational biology and bioinformatics. For Temus, the project is a healthcare use of its “AI Foundry,” part of a national AI program under which it is hiring and deploying Singapore-based AI professionals.

Japan’s Mitsui taps Singapore’s Oncoshot for AI oncology-data platform across IHH hospital network